From α and β to I1: An overview of sympathetic receptors involved in blood pressure control targets for drug treatment

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 3, 1996, Pages

  Van Zwieten, P A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Adrenoceptors; Antihypertensives; Imidazoline receptors; Moxonidine; Rilmenidine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; GUANFACINE; IMIDAZOLINE I1 RECEPTOR AGONIST; IMIDAZOLINE RECEPTOR AGONIST; METHYLDOPA; MOXONIDINE; RAUWOLSCINE; RILMENIDINE; UNCLASSIFIED DRUG; YOHIMBINE; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; DRUG RECEPTOR; IMIDAZOLE DERIVATIVE; IMIDAZOLINE RECEPTORS; OXAZOLE DERIVATIVE; SEROTONIN 1 RECEPTOR; SEROTONIN RECEPTOR;

BLOOD PRESSURE REGULATION; CATECHOLAMINE BLOOD LEVEL; CONFERENCE PAPER; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEART RATE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SEDATION; SYMPATHETIC BLOCKING; XEROSTOMIA; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; DRUG POTENTIATION; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; IMIDAZOLES; OXAZOLES; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, DRUG; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1;

EID: 0029831634     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199627003-00002     Document Type: Conference Paper

References (36)

1. Julius S, Schork N, Schork A. Sympathetic hyperactivity in early stages of hypertension: the Ann Arbor Data Set. J Cardiovasc Pharmacol 1988;12(suppl 3):S121-9.
2. Julius S, Krause L, Schork N, et al. Hyperkinetic borderline hypertension in Tecumseh. Michigan. J Hypertens 1991;9:77-84.
3. Michel MC, Philipp Th, Brodde OE. α- and β-adrenoceptors in hypertension: molecular biology and pharmacological studies. Pharmacol Toxicol 1992;70(suppl 2):S1-10.
4. Van Zwieten PA. Alpha-adrenoceptor-blocking agents in the treatment of hypertension. In: Laragh JH, Brenner BM, eds. Hypertension. 2nd ed. New York: Raven Press, 1995:2917-36.
5. Fitzgerald JD. β-Adrenoceptor antagonists, In: van Zwieten PA, ed. Handbook of hypertension. Vol. 3. New York. Oxford, Amsterdam: Elsevier, 1984:249-306.
6. Prichard BNC, Cruickshank JM. Beta-blockade in hypertension: past, present, and future. In: Laragh JH, Brenner BM, eds. Hypertension. 2nd ed. New York: Raven Press, 1995:2827-60.
7. Boura ALA, Green AF. Depressants of peripheral sympathetic nerve function. In: van Zwieten PA. ed. Handbook of hypertension. Vol. 3. Amsterdam: Elsevier, 1984:194-238.
8. Shore PA, Giachetti A. Reserpine: basic and clinical pharmacology. In: Iversen LL, Iversen SD, Snyder SH, eds. Handbook of psychopharmacology. New York: Plenum Press, 1978:197-211.
9. Chalmers JP, Pilowski PM. Brain stem and bulbospinal neurotransmitter systems in the control of blood pressure. J Hypertens 1991;9:675-94.
10. Minson J, Chalmers JP, Drolet G, et al. Central serotonergic mechanisms in cardiovascular regulation. Cardiovasc Drugs Ther 1989;4:27-32.
11. Michel MC, Ernsberger P. Keeping an eye on the I site: imidazoline-preferring receptors. Trends Pharmacol Sci 1992;13:369-70.
12. Atlas D, Burstein Y. Isolation and partial purification of a clonidine displacing endogenous substance. Eur J Biochem 1984;144:287-93.
13. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. Agmatine: an endogenous "clonidine-displacing" substance in the brain. Science 1994;263:966-9.
14. Head GA, Saunajust F. Importance of imidazoline receptors in the cardiovascular response to clonidine and rilmenidine in conscious rabbits. Fund Clin Pharmacol 1992;6(suppl D):31S-4S.
15. Henning M. α-methyl-DOPA and related compounds. In: van Zwieten PA, ed. Handbook of hypertension. Vol. 3. Pharmacology of antihypertensive drugs. Amsterdam: Elsevier, 1984:154-93.
16. van Zwieten PA, Thoolen MJMC, Timmermans PBVWM. The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. Hypertension 1984;6(suppl 11):28-33.
17. van Zwieten PA, Thoolen MJMC, Timmermans PBMWM. The pharmacological base of the hypotensive activity and side-effects of α-methyl-DOPA, clonidine and guanfacine. Hypertension 1984;6:11-28.
18. 2-adrenoceptor agonists with a central action. Am J Cordiol 1986;57:3E-5E.
19. van Zwieten PA. Different types of centrally acting antihypertensive drugs. Eur Heart J 1992;13(suppl A):18-21.
20. van Zwieten PA, Chalmers JP. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc Drugs Ther 1994;8:787-99.
21. Ernsberger P, Giuliano R, Willette RN, Reid DJ. Role of imidazoline receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990;253:408-18.
22. Tibirica E, Feldman J, Mermet C, Gonon F, Bouquet P. An imidazoline specific mechanism for the hypotensive effect of clonidine: a study with yohimbine and idazoxan. J Pharmacol Exp Ther 1991;256:606-13.
23. Motz W, Strauer BE. Therapy of hypertensive cardiac hypertrophy and impaired coronary microcirculation. J Cardiovasc Pharmacol 1994;24(suppl 1):S34-8.
24. Lavie CJ, Ventura O, Messerli FH. Regression of increased left ventricular mass by antihypertensives. Drugs 1991;42:945-61.
25. Harron DWG. Clinical pharmacology of imidazolines and related compounds. Fund Clin Pharmacol 1992:6(suppl 1):41S-4S.
26. Weitzel G, Pfeiffer B, Stock W. Insulin-like partial effects of agmatine derivatives in adipocytes. Hoppe Sevlers Z Physiol Chem 1980;361:51-60.
27. Kaan EC, Brückner R, Frohly P, Tulp M, Schäfer SG, Zeigler D. Effects of agmatine and moxonidine on glucose metabolism. Cardiovasc Risk Factors 1995;5(suppl 1):19-27.
28. 1-imidazoline receptors. J Cardiovasc Pharmacol 1992; 20(suppl 4):S1-S10.
29. Chrisp P, Failds D. Moxonidine. Drugs 1992;44:993-1012.
30. Dollery CT. Rilmenidine in mild to moderate hypertension. A double-blind, randomised, parallel group multicenter comparison with methyldopa in 157 patients. Curr Ther Res 1990;47:194-221.
31. 2-adrenoceptors to imidazoline preferring receptors. Fund Clin Pharmacol 1992;6(suppl 1):1S-63S.
32. 1-imidazoline receptor agonists in the treatment of hypertension: an appraisal of clinical experience. J Cardiovasc Pharmacol 1994;24(suppl 1):S39-S48.
33. Prichard BNC. Clinical experience with moxonidine. Cardiovasc Drugs Ther 1994;8:49-58.
34. van Zwieten PA, Blauw GJ, van Brummelman P. Serotonergic receptors and drugs in hypertension. Pharmacol Toxicol 1992;70(suppl 2):S17-S22.
35. 1A-receptors in the hypotensive response to urapidil. Am J Cardiol 1989;64:7D-10D.
36. 1-adrenoceptor binding sites show potent hypotensive activity upon central administration. Curr Opin Cardiol 1989;4(suppl 4):S49-S55.